
ClearPoint Neuro Inc.: updates and filings
Price
$7.29
November 19, 2026Market cap $234M
What Ploutos Investor adds for ClearPoint Neuro
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 27% since Oct 28, 2026, when the 10-Q these figures come from was filed ($10.56 then, $7.71 on Nov 18, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 28, 2026next Feb 4, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Material agreement enteredForm8-K
- Nov 18, 2026Shelf registration for future offeringsFormS-3
- Nov 3, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 28, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 28, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 21, 2026Officer or director change, shareholder voteForm8-K
- May 20, 2026Shares registered for employeesFormS-8
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 20, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 10, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 17, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 17, 2026Results of operations, Regulation FD disclosureForm8-K
- Mar 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Feb 20, 2026Filing (amendment)Form144/A
- Feb 9, 2026Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | 8-K | Material agreement entered | Document |
| Nov 18, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 3, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 28, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 28, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 3, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 21, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 20, 2026 | S-8 | Shares registered for employees | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 20, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 10, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 17, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 17, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Mar 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Feb 20, 2026 | 144/A | Filing (amendment) | Document |
| Feb 9, 2026 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 30, 2004. Of its note and share prospectuses (424B, FWP), the newest 40 of 80.
The full analysis
What do ClearPoint Neuro's filings show?
The filings are where every one of ClearPoint Neuro's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.